Xceleron has partnered with Kinetigen, a clinical pharmacology consulting firm specializing in pharmacokinetics, to offer drug developers solutions for robust and cost-effective investigations of Phase I drug pharmacokinetics. Kinetigen will provide its complex PK analyses and overall clinical pharmacology strategies and Xceleron will use its Accelerator Mass Spectrometry (AMS) to gain analytical insight across a broad range of asset classes and matrix types.
“At Xceleron, we believe that technology can get life-changing drugs to people who need them, sooner and at a lower cost. This partnership with Kinetigen will help our clients do that by efficiently and cost-effectively answering critical questions earlier,” said Dr. Michael Butler, chief executive officer of Xceleron.
“Our partnership with Xceleron is very synergistic,” said Dr. Geoffrey Banks, chief executive officer of Kinetigen. “Matching Kinetigen’s PK expertise with Xceleron’s AMS technology is a ‘win-win’ situation for clients seeking more robust options for analysis and interpretation of Phase I PK data.”